Dana M Ciobanu1, Petru A Mircea2, Cornelia Bala3, Adriana Rusu3, Ştefan Vesa4, Gabriela Roman3. 1. Iuliu Hatieganu University of Medicine and Pharmacy, Faculty of Medicine, Department of Diabetes and Nutrition, Cluj-Napoca, Romania. Electronic address: dana.ciobanu@umfcluj.ro. 2. Iuliu Hatieganu University of Medicine and Pharmacy, Faculty of Medicine, Department of the Internal Medicine, Cluj-Napoca, Romania. 3. Iuliu Hatieganu University of Medicine and Pharmacy, Faculty of Medicine, Department of Diabetes and Nutrition, Cluj-Napoca, Romania. 4. Iuliu Hatieganu University of Medicine and Pharmacy, Faculty of Medicine, Department of Pharmacology, Toxicology and Clinical Pharmacology, Cluj-Napoca, Romania.
Abstract
BACKGROUND AND AIM: Endothelial dysfunction is a common feature in hypertension and type 2 diabetes. Whether blood pressure (BP) variability is influencing serum intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) remains to be clarified. We aimed to assess the association between the circulating adhesion molecules and ambulatory blood pressure variability in patients with type 2 diabetes and controls. PATIENTS AND METHODS: The study included data from type 2 diabetes with controlled BP (n = 55), type 2 diabetes with uncontrolled BP (n = 55) and control subjects (n = 28). ICAM-1 and VCAM-1 were measured with specific enzyme-linked immunosorbent assay method. BP variability was assessed using standard deviation of mean systolic and diastolic BP evaluated during 24-hour ambulatory BP monitoring. RESULTS: The uncontrolled BP type 2 diabetes group had significantly higher serum ICAM-1 and VCAM-1 levels compared to controlled BP type 2 diabetes and control groups. In linear regression analysis, after adjustment, higher ICAM-1 was consistently associated with higher daytime and 24-hour diastolic BP variability, and daytime systolic BP variability in the study population. VCAM-1 was associated only with daytime systolic BP variability. CONCLUSIONS: Our study evaluating the association of serum ICAM-1 and VCAM-1 with 24-hour ambulatory BP variability in patients with type 2 diabetes and controls might offer better understanding of the mechanisms generating endothelial dysfunction. Elevated 24-hour ambulatory BP variability might induce endothelial activation by increasing circulating adhesion molecules levels.
BACKGROUND AND AIM: Endothelial dysfunction is a common feature in hypertension and type 2 diabetes. Whether blood pressure (BP) variability is influencing serum intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) remains to be clarified. We aimed to assess the association between the circulating adhesion molecules and ambulatory blood pressure variability in patients with type 2 diabetes and controls. PATIENTS AND METHODS: The study included data from type 2 diabetes with controlled BP (n = 55), type 2 diabetes with uncontrolled BP (n = 55) and control subjects (n = 28). ICAM-1 and VCAM-1 were measured with specific enzyme-linked immunosorbent assay method. BP variability was assessed using standard deviation of mean systolic and diastolic BP evaluated during 24-hour ambulatory BP monitoring. RESULTS: The uncontrolled BP type 2 diabetes group had significantly higher serum ICAM-1 and VCAM-1 levels compared to controlled BP type 2 diabetes and control groups. In linear regression analysis, after adjustment, higher ICAM-1 was consistently associated with higher daytime and 24-hour diastolic BP variability, and daytime systolic BP variability in the study population. VCAM-1 was associated only with daytime systolic BP variability. CONCLUSIONS: Our study evaluating the association of serum ICAM-1 and VCAM-1 with 24-hour ambulatory BP variability in patients with type 2 diabetes and controls might offer better understanding of the mechanisms generating endothelial dysfunction. Elevated 24-hour ambulatory BP variability might induce endothelial activation by increasing circulating adhesion molecules levels.
Authors: Jeanie B Tryggestad; Rachana D Shah; Barbara H Braffett; Fida Bacha; Samuel S Gidding; Rose A Gubitosi-Klug; Amy S Shah; Elaine M Urbina; Lorraine E Levitt Katz Journal: Pediatr Diabetes Date: 2020-07-02 Impact factor: 4.866
Authors: Piotr Skrzypczyk; Anna Ozimek; Anna Ofiara; Michał Szyszka; Jarosław Sołtyski; Anna Stelmaszczyk-Emmel; Elżbieta Górska; Małgorzata Pańczyk-Tomaszewska Journal: Cent Eur J Immunol Date: 2019-09-30 Impact factor: 2.085